Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation

被引:2
|
作者
Sung, Chao-Hsien [1 ]
Tsuang, Fon-Yih [2 ]
Lin, Chih-Peng [3 ]
Chan, Kuang-Cheng [3 ]
Chou, Wei-Han [3 ]
Wu, Chun-Yu [3 ]
机构
[1] Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Dept Anesthesiol, New Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Neurosurg, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Anesthesiol, 7 Chung Shan S Rd, Taipei, Taiwan
关键词
CENTRAL-NERVOUS-SYSTEM; CANCER RECURRENCE; GLIOBLASTOMA; CELL; ANESTHESIA; SURVIVAL; CATECHOLAMINES; CYTOTOXICITY; PROPOFOL; SURGERY;
D O I
10.1038/s41598-021-95851-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
High-grade gliomas are notorious for a high recurrence rate even after curative resection surgery. Studies regarding the influence of scalp block on high-grade gliomas have been inconclusive, possibly because the condition's most important genetic mutation profile, namely the isocitrate dehydrogenase 1 (IDH1) mutation, had not been analyzed. Therefore, we conducted a single-center study including patients with high-grade glioma who underwent tumor resection between January 2014 and December 2019. Kaplan-Meier survival analysis revealed that scalp block was associated with longer progression-free survival (PFS; 15.17 vs. 10.77 months, p = 0.0018), as was the IDH1 mutation (37.37 vs. 10.90 months, p = 0.0149). Multivariate Cox regression analysis revealed that scalp block (hazard ratio: 0.436, 95% confidence interval: 0.236-0.807, p = 0.0082), gross total resection (hazard ratio: 0.405, 95% confidence interval: 0.227-0.721, p = 0.0021), and IDH1 mutation (hazard ratio: 0.304, 95% confidence interval: 0.118-0.784, p = 0.0138) were associated with better PFS. Our results demonstrate that application of scalp block, regardless of IDH1 profile, is an independent factor associated with longer PFS for patients with high-grade glioma.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] A Phase 1 Dose-Escalation Study of Oral 5-Aminolevulinic Acid in Adult Patients Undergoing Resection of a Newly Diagnosed or Recurrent High-Grade Glioma
    Cozzens, Jeffrey W.
    Lokaitis, Barbara C.
    Moore, Brian E.
    Amin, Devin V.
    Espinosa, Jose A.
    MacGregor, Margaret
    Michael, Alex P.
    Jones, Breck A.
    NEUROSURGERY, 2017, 81 (01) : 46 - 55
  • [42] Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
    Nazari, P. Mir Seyed
    Riedl, J.
    Preusser, M.
    Posch, F.
    Thaler, J.
    Marosi, C.
    Birner, P.
    Ricken, G.
    Hainfellner, J. A.
    Pabinger, I.
    Ay, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (06) : 1121 - 1127
  • [43] Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes
    Gupta, Meetakshi
    Anjari, Mustafa
    Brandner, Sebastian
    Fersht, Naomi
    Wilson, Elena
    Thust, Steffi
    Kosmin, Michael
    BIOMEDICINES, 2024, 12 (04)
  • [44] Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment
    July, Julius
    Patricia, Diana
    Gunawan, Pricilla Yani
    Setiajaya, Handrianto
    Ginting, Teridah Ernala
    Putra, Teguh Pribadi
    Wuisan, Zerlina
    Budhiarko, Dini
    Masykura, Najmiatul
    Prayogi, Gintang
    Utomo, Ahmad Rusdan
    Tandean, Steven
    Loe, Michael Lumintang
    PAN AFRICAN MEDICAL JOURNAL, 2020, 36 : 1 - 13
  • [45] The Effect of WT-1 Positivity on Survival Outcomes in Patients with High-grade Serous Epithelial Ovarian Cancer
    Karakas, Sema
    Tunca, Aysun Fendal
    Altinay, Serdar
    Yildiz, Gunes Ozlem
    Ekin, Murat
    MEDICAL JOURNAL OF BAKIRKOY, 2022, 18 (02) : 151 - 156
  • [46] Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in- human trial
    Umemura, Yoshie
    Orringer, Daniel
    Junck, Larry
    Varela, Maria L.
    West, Molly E. J.
    Faisal, Syed M.
    Comba, Andrea
    Heth, Jason
    Sagher, Oren
    Leung, Denise
    Mammoser, Aaron
    Hervey-Jumper, Shawn
    Zamler, Daniel
    Yadav, Viveka N.
    Dunn, Patrick
    Al-Holou, Wajd
    Hollon, Todd
    Kim, Michelle M.
    Wahl, Daniel R.
    Camelo-Piragua, Sandra
    Lieberman, Andrew P.
    Venneti, Sriram
    Mckeever, Paul
    Lawrence, Theodore
    Kurokawa, Ryo
    Sagher, Karen
    Altshuler, David
    Zhao, Lili
    Muraszko, Karin
    Castro, Maria G.
    Lowenstein, Pedro
    LANCET ONCOLOGY, 2023, 24 (09) : 1042 - 1052
  • [47] Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region
    Ayoub, Zeina
    Geara, Fady
    Najjar, Marwan
    Comair, Youssef
    Khoueiry-Zgheib, Nathalie
    Khoueiry, Pierre
    Mahfouz, Rami
    Boulos, Fouad I.
    Kamar, Francois G.
    Andraos, Therese
    Saadeh, Fadi
    Kreidieh, Firas
    Abboud, Miguel
    Skaf, Ghassan
    Assi, Hazem I.
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2019, 182 : 92 - 97
  • [48] TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients
    Kluckova, K.
    Kozak, J.
    Szaboova, K.
    Rychly, B.
    Svajdler, M.
    Suchankova, M.
    Tibenska, E.
    Filova, B.
    Steno, J.
    Matejcik, V.
    Homolova, M.
    Bucova, M.
    MEDIATORS OF INFLAMMATION, 2020, 2020
  • [49] Evaluation of frailty, cognitive function, and age as prognostic factors for survival in patients with IDH1wild-type high-grade glioma
    Smrdel, Andreja Cirila Skufca
    Podlesek, Anja
    Markovic, Jana
    Jereb, Jana
    Vidmar, Marija Skoblar
    Smrdel, Uros
    JOURNAL OF PSYCHOSOCIAL ONCOLOGY RESEARCH AND PRACTICE, 2024, 6 (03):
  • [50] Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion
    Kawaguchi, Tomohiro
    Sonoda, Yukihiko
    Shibahara, Ichiyo
    Saito, Ryuta
    Kanamori, Masayuki
    Kumabe, Toshihiro
    Tominaga, Teiji
    JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (03) : 505 - 514